ZIP14 Affects the Proliferation, Apoptosis, and Migration of Cervical Cancer Cells by Regulating the P38 MAPK Pathway
CONCLUSION: Our study is the first to elucidate the pivotal role of ZIP14 in the pathogenesis of CC, revealing its inhibitory effects through the activation of the p38 MAPK signaling pathway. The discovery not only provides a deeper understanding of CC's molecular underpinnings, but also highlights ZIP14 as a promising therapeutic target. As ZIP14 holds significant potential for therapeutic interventions, our findings lay a robust foundation for further studies and pave the way for the exploration of novel treatment modalities for cervical cancer.PMID:37990424 | DOI:10.2174/0115680096250711231024063841 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 22, 2023 Category: Cancer & Oncology Authors: Lixia Jiang Ting Xie Yu Xia Feng Li Tianyu Zhong Mi Lai Source Type: research
High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma
CONCLUSION: Adropin overexpression in PDA promotes cancer cell proliferation and angiogenesis in tumor microenvironment by continuously activating VEGFR2 signaling, thereby creating conditions for tumor progression. Thus, targeting adropin may be an effective anti-PDA strategy.PMID:37990897 | DOI:10.2174/0115680096267203231024093601 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 22, 2023 Category: Cancer & Oncology Authors: Jilong Hu QinRong Wu QunHua Ding WeiBo Wu Qiyun Li Zhinan Zheng Source Type: research
Denosumab Induces Neoplastic Stromal Cell Apoptosis via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone
CONCLUSION: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.PMID:37961860 | DOI:10.2174/0115680096265253231022185008 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Xianwei Chen Fan Ye Hao He Gong Chen Zhifu Chen En Ye Bingjan He Yuqi Yang Jing Zhang Source Type: research
The Role of Vasodilator-stimulated Phosphoproteins in the Development of Malignant Tumors
This study provides a new theoretical basis for clinical molecular diagnosis and molecular targeted therapy.PMID:37962042 | DOI:10.2174/0115680096262439231023110106 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Jiandong Gui Hangsheng Zhou Hongyuan Wan Dongjie Yang Qing Liu Lijie Zhu Yuanyuan Mi Source Type: research
Denosumab Induces Neoplastic Stromal Cell Apoptosis via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone
CONCLUSION: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.PMID:37961860 | DOI:10.2174/0115680096265253231022185008 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Xianwei Chen Fan Ye Hao He Gong Chen Zhifu Chen En Ye Bingjan He Yuqi Yang Jing Zhang Source Type: research
The Role of Vasodilator-stimulated Phosphoproteins in the Development of Malignant Tumors
This study provides a new theoretical basis for clinical molecular diagnosis and molecular targeted therapy.PMID:37962042 | DOI:10.2174/0115680096262439231023110106 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Jiandong Gui Hangsheng Zhou Hongyuan Wan Dongjie Yang Qing Liu Lijie Zhu Yuanyuan Mi Source Type: research
Denosumab Induces Neoplastic Stromal Cell Apoptosis via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone
CONCLUSION: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.PMID:37961860 | DOI:10.2174/0115680096265253231022185008 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Xianwei Chen Fan Ye Hao He Gong Chen Zhifu Chen En Ye Bingjan He Yuqi Yang Jing Zhang Source Type: research
The Role of Vasodilator-stimulated Phosphoproteins in the Development of Malignant Tumors
This study provides a new theoretical basis for clinical molecular diagnosis and molecular targeted therapy.PMID:37962042 | DOI:10.2174/0115680096262439231023110106 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Jiandong Gui Hangsheng Zhou Hongyuan Wan Dongjie Yang Qing Liu Lijie Zhu Yuanyuan Mi Source Type: research
Denosumab Induces Neoplastic Stromal Cell Apoptosis via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone
CONCLUSION: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.PMID:37961860 | DOI:10.2174/0115680096265253231022185008 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Xianwei Chen Fan Ye Hao He Gong Chen Zhifu Chen En Ye Bingjan He Yuqi Yang Jing Zhang Source Type: research
The Role of Vasodilator-stimulated Phosphoproteins in the Development of Malignant Tumors
This study provides a new theoretical basis for clinical molecular diagnosis and molecular targeted therapy.PMID:37962042 | DOI:10.2174/0115680096262439231023110106 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Jiandong Gui Hangsheng Zhou Hongyuan Wan Dongjie Yang Qing Liu Lijie Zhu Yuanyuan Mi Source Type: research
Denosumab Induces Neoplastic Stromal Cell Apoptosis via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone
CONCLUSION: Denosumab induced neoplastic stromal cells apoptosis via p62 downregulation dependent on autophagy pathway. The combination of p62 and RANKL knockdown might be a better strategy than RANKL knockdown alone for GCTB targeted therapy.PMID:37961860 | DOI:10.2174/0115680096265253231022185008 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Xianwei Chen Fan Ye Hao He Gong Chen Zhifu Chen En Ye Bingjan He Yuqi Yang Jing Zhang Source Type: research
The Role of Vasodilator-stimulated Phosphoproteins in the Development of Malignant Tumors
This study provides a new theoretical basis for clinical molecular diagnosis and molecular targeted therapy.PMID:37962042 | DOI:10.2174/0115680096262439231023110106 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2023 Category: Cancer & Oncology Authors: Jiandong Gui Hangsheng Zhou Hongyuan Wan Dongjie Yang Qing Liu Lijie Zhu Yuanyuan Mi Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
